Search Immortality Topics:

Page 9«..891011..2030..»


Stem Cell Injections in Mexico Led to Drug-Resistant Infections – Medpage Today

Posted: May 15, 2024 at 2:33 am

Three patients developed difficult-to-treat Mycobacterium abscessus infections after receiving embryonic stem cell injections in Mexico in 2022, researchers reported.

Two men -- one from Colorado and one from Arizona -- acquired the infections in Guadalajara and Baja California, Mexico, from donor embryonic stem cell injections for joint pain, reported Minh-Vu H. Nguyen, MD, of National Jewish Health in Denver, and co-authors in Morbidity and Mortality Weekly Report.

The Arizona man (Patient B) had received an injection for psoriatic arthritis in the right elbow. The Colorado man (Patient C) had had bilateral knee injections for osteoarthritis, and developed infections in both knees.

"Historically, stem cell treatments have been linked to bacterial infections, and procedure-related infection risks associated with medical tourism are known," wrote Nguyen and co-authors. "Providers and public health agencies need to be aware of the risk for M. abscessus infections from stem cell treatments" not approved by the FDA, they added.

Previously, a Colorado woman (Patient A) had received intrathecal donor embryonic stem cell injections, also in Baja California, to treat her multiple sclerosis and also contracted an M. abscessus infection.

The researchers were only able to obtain original isolates from patients A and B, and performed whole-genome sequencing and phylogenetic analyses, which found that the two core genomes were distinct from known dominant circulating clones.

"Given that the isolates identified from patients treated at different, distant clinics represent a single clone, the physicians and CDPHE [Colorado Department of Public Health and Environment] suspect a common infected source (potentially the product, reagents, or equipment used) for patients A and B," noted Nguyen and co-authors.

The Baja California clinics where patients A and B were treated were 167 miles apart.

According to the CDC, M. abscessus is a distant relative of the bacterium that causes tuberculosis and leprosy. "People with open wounds or who receive injections without appropriate skin disinfection may be at risk for infection by M. abscessus," the agency noted. The mycobacteria is found in water, soil, and dust, and has been known to contaminate medications and other medical products.

M. abscessus is intrinsically drug-resistant and rapidly growing, according to Nguyen and co-authors, which can make it hard to treat with antibiotics normally used to treat skin infections. Symptoms can include fever, chills, and muscle aches.

The Arthritis Foundation recommends using caution in considering stem cell injections. "It's important to know that no stem cell interventions are currently approved by the FDA for any type of arthritis or joint injury, although you may see advertisements for them and read about celebrities getting these interventions," they wrote in a publication on considerations for patients.

Clinics offering stem cell therapies both in the U.S. and abroad can often target vulnerable patients, suggesting that the unproven therapies can treat chronic or incurable conditions. An investigation by MedPage Today last year found that patients were being harmed by autologous stem cell injections being sold as part of a "clinical trial."

The three patients are receiving ongoing care as of March 28, and no additional cases have been identified. The CDPHE attempted to contact the clinics that performed the stem cell injections, but did not get a response.

According to Nguyen and colleagues, the next steps will include performing whole-genome sequencing on new samples obtained from patient C, sharing the information, and continuing to look for other cases.

Sophie Putka is an enterprise and investigative writer for MedPage Today. Her work has appeared in the Wall Street Journal, Discover, Business Insider, Inverse, Cannabis Wire, and more. She joined MedPage Today in August of 2021. Follow

Disclosures

Nguyen reported financial relationships with Oregon Health & Science University.

Co-authors reported financial relationships with Insmed, RedHill Biopharma, Paratek Pharmaceuticals, AN2 Therapeutics, Spero Therapeutics, MannKind Corporation, Bugworks, Juvabis, Genentech, Pfizer, Otsuka, Eli Lilly, AstraZeneca, Hyfe, Matinas Biopharma, Nob Hill Therapeutics, Zambon, the Patient-Centered Outcomes Research Institute, the Cystic Fibrosis Foundation, the Bill and Melinda Gates Foundation, the FDA, and the NIH.

Primary Source

Morbidity and Mortality Weekly Report

Source Reference: Nguyen MH, et al "Potential outbreak of extrapulmonary mycobacterium abscessus subspecies massiliense infections from stem cell treatment clinics in Mexico -- Arizona and Colorado, 2022" MMWR 2024; DOI: 10.15585/mmwr.mm7318a3.

See the article here:
Stem Cell Injections in Mexico Led to Drug-Resistant Infections - Medpage Today

Recommendation and review posted by G. Smith

Advances and challenges of the cell-based therapies among diabetic patients – Journal of Translational Medicine – Journal of Translational Medicine

Posted: May 15, 2024 at 2:33 am

Vos T, Lim SS, Abbafati C, Abbas KM, Abbasi M, Abbasifard M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 19902019: a systematic analysis for the global burden of Disease Study 2019. Lancet. 2020;396(10258):120422.

Article Google Scholar

Cho NH, Shaw J, Karuranga S, Huang Y, da Rocha Fernandes J, Ohlrogge A, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:27181.

Article CAS PubMed Google Scholar

Moghbeli M, Naghibzadeh B, Ghahraman M, Fatemi S, Taghavi M, Vakili R, et al. Mutations in HNF1A gene are not a Common cause of familial young-onset diabetes in Iran. Indian J Clin Biochem. 2018;33(1):915.

Article CAS PubMed Google Scholar

Akhlaghipour I, Bina AR, Mogharrabi MR, Fanoodi A, Ebrahimian AR, Khojasteh Kaffash S, et al. Single-nucleotide polymorphisms as important risk factors of diabetes among Middle East population. Hum Genomics. 2022;16(1):11.

Article CAS PubMed PubMed Central Google Scholar

Moghbeli M, Khedmatgozar H, Yadegari M, Avan A, Ferns GA, Ghayour Mobarhan M. Cytokines and the immune response in obesity-related disorders. Adv Clin Chem. 2021;101:13568.

Article CAS PubMed Google Scholar

Eizirik DL, Pasquali L, Cnop M. Pancreatic -cells in type 1 and type 2 diabetes mellitus: different pathways to failure. Nat Reviews Endocrinol. 2020;16(7):34962.

Article CAS Google Scholar

Siqueira ISLd, Alves Guimares R, Mamed SN, Santos TAP, Rocha SD, Pagotto V, et al. Prevalence and risk factors for self-report diabetes mellitus: a population-based study. Int J Environ Res Public Health. 2020;17(18):6497.

Article Google Scholar

Free radical research.

Zhu B, Qu S. The relationship between diabetes mellitus and cancers and its underlying mechanisms. Front Endocrinol. 2022;13:800995.

Article Google Scholar

Mojarrad M, Moghbeli M. Genetic and molecular biology of bladder cancer among Iranian patients. Mol Genet Genomic Med. 2020;8(6):e1233.

Article PubMed PubMed Central Google Scholar

Moghbeli M. Genetic and molecular biology of breast cancer among Iranian patients. J Transl Med. 2019;17(1):218.

Article PubMed PubMed Central Google Scholar

Abbaszadegan MR, Moghbeli M. Genetic and molecular origins of colorectal Cancer among the iranians: an update. Diagn Pathol. 2018;13(1):97.

Article CAS PubMed PubMed Central Google Scholar

Kim I. A brief overview of cell therapy and its product. J Korean Association Oral Maxillofacial Surg. 2013;39(5):201.

Article Google Scholar

Mount NM, Ward SJ, Kefalas P, Hyllner J. Cell-based therapy technology classifications and translational challenges. Philosophical Trans Royal Soc B: Biol Sci. 2015;370(1680):20150017.

Article Google Scholar

El-Kadiry AE-H, Rafei M, Shammaa R. Cell therapy: types, regulation, and clinical benefits. Front Med. 2021;8:756029.

Article Google Scholar

Squifflet J-P, Gruessner R, Sutherland D. The history of pancreas transplantation: past, present and future. Acta Chir Belg. 2008;108(3):36778.

Article PubMed Google Scholar

Parums DV. First Regulatory approval for allogeneic pancreatic islet Beta cell infusion for adult patients with type 1 diabetes Mellitus. Med Sci Monitor: Int Med J Experimental Clin Res. 2023;29:e9419181.

Article Google Scholar

Yang L, Hu Z-M, Jiang F-X, Wang W. Stem cell therapy for insulin-dependent diabetes: are we still on the road? World J Stem Cells. 2022;14(7):503.

Article PubMed PubMed Central Google Scholar

Affan M, Dar MS. Donislecel-the first approved pancreatic islet cell therapy medication for type 1 diabetes: a letter to the editor. Ir J Med Sci (1971-). 2023:12.

Harris E. FDA greenlights first cell therapy for adults with type 1 diabetes. JAMA. 2023.

Soon-Shiong P, Heintz R, Merideth N, Yao Q, Yao Z, Zheng T, et al. Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet (London England). 1994;343(8903):9501.

Article CAS PubMed Google Scholar

Calafiore R, Basta G, Luca G, Lemmi A, Montanucci MP, Calabrese G, et al. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases. Diabetes Care. 2006;29(1):1378.

Article PubMed Google Scholar

Tuch BE, Keogh GW, Williams LJ, Wu W, Foster JL, Vaithilingam V, et al. Safety and viability of microencapsulated human islets transplanted into diabetic humans. Diabetes Care. 2009;32(10):18879.

Article CAS PubMed PubMed Central Google Scholar

Weng L, Wang X, Liu H, Yu Z, Liu S. Light-responsive microneedle array with tunable insulin release function for painless and on-demand anti-diabetic therapy. Mater Lett. 2023:135684.

Okcu A, Yazir Y, imek T, Mert S, Duruksu G, ztrk A, et al. Investigation of the effect of pancreatic decellularized matrix on encapsulated islets of Langerhans with mesenchymal stem cells. Tissue Cell. 2023;82:102110.

Article CAS PubMed Google Scholar

Khaliq T, Sohail M, Minhas MU, Mahmood A, Munir A, Qalawlus AHM, et al. Hyaluronic acid/alginate-based biomimetic hydrogel membranes for accelerated diabetic wound repair. Int J Pharm. 2023;643:123244.

Article CAS PubMed Google Scholar

Kuwabara R, Qin T, Llacua LA, Hu S, Boekschoten MV, de Haan BJ, et al. Extracellular matrix inclusion in immunoisolating alginate-based microcapsules promotes longevity, reduces fibrosis, and supports function of islet allografts in vivo. Acta Biomater. 2023;158:15162.

Article CAS PubMed Google Scholar

Kirk K, Hao E, Lahmy R, Itkin-Ansari P. Human embryonic stem cell derived islet progenitors mature inside an encapsulation device without evidence of increased biomass or cell escape. Stem cell Res. 2014;12(3):80714.

Article CAS PubMed Google Scholar

Dufrane D, van Steenberghe M, Goebbels R-M, Saliez A, Guiot Y, Gianello P. The influence of implantation site on the biocompatibility and survival of alginate encapsulated pig islets in rats. Biomaterials. 2006;27(17):32018.

Article CAS PubMed Google Scholar

Pullen LC. Stem cellderived pancreatic progenitor cells have now been transplanted into patients: report from IPITA 2018. Wiley Online Library; 2018. pp. 15812.

Dang HP, Chen H, Dargaville TR, Tuch BE. Cell delivery systems: toward the next generation of cell therapies for type 1 diabetes. J Cell Mol Med. 2022;26(18):475667.

Article CAS PubMed PubMed Central Google Scholar

Viacyte. ViaCyte and gore enter clinical phase agreement based on novel membrane technology for PEC-encap product candidate. 2020.

Viacyte. viacyte announces initiation of phase 2 study of encapsulated cell therapy for type 1 diabetes patients 2021 2021. https://viacyte.com/press-releases/viacyteannouncesinitiationofphase2studyofencapsulatedcelltherapyfortype1diabetespatients/.

Hodgson J. Drug pipeline 3Q23ERT, bispecifics and CRISPR in sickle cell disease. Nat Biotechnol. 2023;41(11):1498500.

Article CAS PubMed Google Scholar

Pagliuca F. Pre-clinical proof-of-Concept in two lead programs in type 1 diabetes. International Socety for Stem Cell Research; 2019.

Jones PM, Persaud SJ. -cell replacement therapy for type 1 diabetes: closer and closer. Diabet Med. 2022;39(6).

Carlsson P-O, Espes D, Sedigh A, Rotem A, Zimerman B, Grinberg H, et al. Transplantation of macroencapsulated human islets within the bioartificial pancreas Air to patients with type 1 diabetes mellitus. Am J Transplant. 2018;18(7):173544.

Article CAS PubMed PubMed Central Google Scholar

Ludwig B, Zimerman B, Steffen A, Yavriants K, Azarov D, Reichel A, et al. A novel device for islet transplantation providing immune protection and oxygen supply. Horm Metab Res. 2010;42(13):91822.

Article CAS PubMed Google Scholar

Evron Y, Colton CK, Ludwig B, Weir GC, Zimermann B, Maimon S, et al. Long-term viability and function of transplanted islets macroencapsulated at high density are achieved by enhanced oxygen supply. Sci Rep. 2018;8(1):6508.

Article PubMed PubMed Central Google Scholar

Cao R, Avgoustiniatos E, Papas K, de Vos P, Lakey JR. Mathematical predictions of oxygen availability in micro-and macroencapsulated human and porcine pancreatic islets. J Biomedical Mater Res Part B: Appl Biomaterials. 2020;108(2):34352.

Article CAS Google Scholar

Gala-Lopez B, Pepper A, Dinyari P, Malcolm A, Kin T, Pawlick L, et al. Subcutaneous clinical islet transplantation in a prevascularized subcutaneous pouchpreliminary experience. CellR4. 2016;4(5):e2132.

Google Scholar

Sernova Corp Presents Positive Preliminary. Safety and Efficacy Data in its Phase I/II Clinical Trial for Type-1 Diabetes: Biospace. https://www.biospace.com/article/sernovacorppresentspositivepreliminarysafetyandefficacydatainitsphaseiiiclinicaltrialfortype1diabetes/.

Bachul PJ, Perez-Gutierrez A, Juengel B, Golab K, Basto L, Perea L et al. 306-OR: modified approach for improved isllotransplantation into prevascularized sernova cell pouch device: preliminary results of the phase i/ii clinical trial at University of Chicago. Diabetes. 2022;71(Supplement_1).

Vegas AJ, Veiseh O, Doloff JC, Ma M, Tam HH, Bratlie K, et al. Combinatorial hydrogel library enables identification of materials that mitigate the foreign body response in primates. Nat Biotechnol. 2016;34(3):34552.

Article CAS PubMed PubMed Central Google Scholar

Vegas AJ, Veiseh O, Grtler M, Millman JR, Pagliuca FW, Bader AR, et al. Long-term glycemic control using polymer-encapsulated human stem cellderived beta cells in immune-competent mice. Nat Med. 2016;22(3):30611.

Article CAS PubMed PubMed Central Google Scholar

Shapiro AD, Konkle BA, Croteau SE, Miesbach WA, Hay CRM, Kazmi R, et al. First-in-human phase 1/2 clinical trial of SIG-001, an innovative shielded cell therapy platform, for hemophilia . Blood. 2020;136:8.

Google Scholar

Taraballi F, Sushnitha M, Tsao C, Bauza G, Liverani C, Shi A, et al. Biomimetic tissue engineering: tuning the immune and inflammatory response to implantable biomaterials. Adv Healthc Mater. 2018;7(17):1800490.

Article CAS Google Scholar

Yesilyurt V, Veiseh O, Doloff JC, Li J, Bose S, Xie X, et al. A facile and versatile method to endow biomaterial devices with zwitterionic surface coatings. Adv Healthc Mater. 2017;6(4):1601091.

Article Google Scholar

Liu Q, Chiu A, Wang L-H, An D, Zhong M, Smink AM, et al. Zwitterionically modified alginates mitigate cellular overgrowth for cell encapsulation. Nat Commun. 2019;10(1):5262.

Article PubMed PubMed Central Google Scholar

Noverraz F, Montanari E, Pimenta J, Szab L, Ortiz D, Gonelle-Gispert C, et al. Antifibrotic effect of ketoprofen-grafted alginate microcapsules in the transplantation of insulin producing cells. Bioconjug Chem. 2018;29(6):193241.

Article CAS PubMed Google Scholar

Jeon SI, Jeong J-H, Kim JE, Haque MR, Kim J, Byun Y, et al. Synthesis of PEG-dendron for surface modification of pancreatic islets and suppression of the immune response. J Mater Chem B. 2021;9(11):263140.

Article CAS PubMed Google Scholar

Derakhshankhah H, Sajadimajd S, Jahanshahi F, Samsonchi Z, Karimi H, Hajizadeh-Saffar E, et al. Immunoengineering Biomaterials in Cell-based therapy for type 1 diabetes. Tissue Eng Part B: Reviews. 2022;28(5):105366.

Article CAS Google Scholar

Piemonti L, Maffi P, Nano R, Bertuzzi F, Melzi R, Mercalli A, et al. Treating diabetes with islet transplantation: lessons from the Milan experience. Transplantation, Bioengineering, and regeneration of the endocrine pancreas. Elsevier; 2020. pp. 64558.

Azzi J, Tang L, Moore R, Tong R, El Haddad N, Akiyoshi T, et al. Polylactide-cyclosporin A nanoparticles for targeted immunosuppression. FASEB J. 2010;24(10):3927.

Article CAS PubMed PubMed Central Google Scholar

Chen X, Liu H, Li H, Cheng Y, Yang L, Liu Y. In vitro expansion and differentiation of rat pancreatic duct-derived stem cells into insulin secreting cells using a dynamic three-dimensional cell culture system. Genet Mol Res. 2016;15(2).

Becker MW, Simonovich JA, Phelps EA. Engineered microenvironments and microdevices for modeling the pathophysiology of type 1 diabetes. Biomaterials. 2019;198:4962.

Article CAS PubMed Google Scholar

Graham JG, Zhang X, Goodman A, Pothoven K, Houlihan J, Wang S, et al. PLG scaffold delivered antigen-specific regulatory T cells induce systemic tolerance in autoimmune diabetes. Tissue Eng Part A. 2013;19(1112):146575.

Read more:
Advances and challenges of the cell-based therapies among diabetic patients - Journal of Translational Medicine - Journal of Translational Medicine

Recommendation and review posted by G. Smith

Fighting the Signs of Aging with Stem Treatments: Is it Effective? A Regenerative Medicine Expert Explains – Washington Times

Posted: May 15, 2024 at 2:33 am

When people hear the term anti-aging, cosmetic procedures like Botox or reliance on topical skincare products such as serums and creams often come to mind. However, beyond these conventional approaches, a pioneering treatment has offered an alternative solution to address the multifaceted concerns of aging: stem cell treatments.

From the name itself, stem cell treatments utilize cells' regenerative capabilities, which can transform into various specialized cell types. These treatments address autoimmune diseases and the intrinsic signs of aging.

To clarify this therapy, Dr. Ernesto Romero, a renowned specialist in regenerative medicine at the Immunotherapy Regenerative Medicine Clinic in Mexico, shares his insights. With nearly two decades of experience in the field and successful client stories, Dr. Romero understands the holistic approach to stem cell research and clinical application.

Aging as a Holistic Complex Concern

Aging concerns extend beyond the appearance of wrinkles and fine lines on the skin. For Dr. Romero, aging is a complex interplay of physical, emotional, and hormonal factors that significantly impact various aspects of health and well-being.

As individuals age, they may experience andropause (in men) or menopause and post-menopause (in women), which can profoundly affect their quality of life. These hormonal changes can lead to a range of symptoms, including decreased libido, fatigue, mood swings, sleep disturbances, and cognitive decline. Moreover, the aging process can also result in a decline in physical function, increased risk of chronic diseases, and a general sense of diminished vitality.

Aging-related challenges are multifaceted and require a comprehensive approach. Dr. Romero opines that this is where stem cell therapy for anti-aging works best. Designed to rejuvenate the body comprehensively by regenerating damaged tissues and organs, it addresses the root causes of aging symptoms, not just external appearances.

Some Stem Cell Therapies for Aging Concerns

Addressing aging concerns may seem complicated, but regenerative medicine offers several innovative stem cell approaches. According to Dr. Romero, one such method is Plasma rich in Bioactive Proteins (PRP-B), which harnesses the healing powers of platelets in blood clotting.

PRP-B is enriched with growth factors and bioactive proteins that stimulate tissue repair, blood vessel formation, and cellular regeneration. Dr. Romero mentions that this approach is particularly beneficial for those looking to enhance the body's natural healing processes and rejuvenate aging tissues at a cellular level.

Another advanced treatment uses Mesenchymal Stem Cells (MSCs) in IV rejuvenation and anti-aging facelifts to improve aging skin concerns like elasticity, firmness, and wrinkles. Dr. Romero notes that MSCs in facelifts significantly enhance skin texture and reduce scars, boosting youthfulness and self-confidence.

Complementary therapies such as ozone therapy and plasmapheresis further amplify the effects of stem cell treatments. Ozone therapy improves cellular oxygenation and fights inflammation and oxidative stress, while plasmapheresis purifies the blood and enhances microcirculation.

Dr. Romero notes, "While these therapies may sound complex, they ultimately address the root causes of aging, providing long-lasting and superior results compared to more superficial and quick-fix treatments."

How Immunoterhpay Regenerative Medicine Leads the Way

Dr. Romero and his expert team strive to ease the stress of addressing aging by upholding the highest quality standards in their stem cell treatments. They use fresh, non-frozen cells from their nearby laboratory, just 15 minutes from the clinic, to ensure optimal stem cell conditions for the best treatment outcomes.

High-quality stem cell treatments from Immunotherapy Regenerative Medicine enable individuals to pursue their passions without the limitations of aging, enhancing their dignity and quality of life.

See the original post here:
Fighting the Signs of Aging with Stem Treatments: Is it Effective? A Regenerative Medicine Expert Explains - Washington Times

Recommendation and review posted by G. Smith

The CDC issues a report about infections from stem-cell treatments in Mexico – Denver 7 Colorado News

Posted: May 15, 2024 at 2:33 am

MEXICO CITY (AP) The U.S. Centers for Disease Control and Prevention has issued a report about three cases of infections apparently linked to stem-cell treatments American patients received in Mexico. The CDC issued the report Thursday on infections of Non-Tuberculous Mycobacteria (NTM), which it described as difficult-to-treat and intrinsically drug-resistant. All three patients detected at two Colorado hospitals remain in treatment. The infections were apparently acquired during stem-cell injections carried out at two different clinics in the Mexican border state of Baja California. In the past, Americans and Mexicans have suffered infections apparently because some doctors in Mexico were taking multiple doses of anesthetics from a single vial due to shortages or other problems.

To read the full report from the CDC, click here.

Denver 7+ Colorado News Latest Headlines | May 10, 8am

Read more here:
The CDC issues a report about infections from stem-cell treatments in Mexico - Denver 7 Colorado News

Recommendation and review posted by G. Smith

Three drug-resistant infections in US tied to stem-cell injections in Mexico – University of Minnesota Twin Cities

Posted: May 15, 2024 at 2:33 am

Editor's Note: This story was updated at 3:50pm

An investigation by clinicians and public health officials from Colorado and Arizona has linked a cluster of antibiotic-resistant infections in three US residents to embryonic stem-cell injections at clinics in Mexico.

In a report published today in Morbidity and Mortality Weekly Report (MMWR), the investigators said the infections were caused by Mycobacterium abscessus, an intrinsically drug-resistant species of nontuberculosis mycobacterium that has previously been associated with medical tourism. The first patient, a Colorado woman (patient A) with multiple sclerosis, was treated for M abscessus meningitis at two Colorado hospitals (hospitals A and B) in November-December 2022 following an intrathecal donor stem-cell injection in Baja California, Mexico, in October 2022.

Two additional patients were identified at hospital BNational Jewish Health in Denverin the spring of 2023. The first (patient B) was a man from Arizona who developed a right elbow osteoarticular infection following a donor stem-cell injection for psoriatic arthritis at a different clinic in Baja in April 2022. The second was a Colorado man (patient C) who developed infections in both knees after receiving stem-cell injections in his knees at a clinic in Guadalajara in October 2022.

As a world-renowned referral center for patients with mycobacterial diseases, we see patients from all over the country, and we noticed a trend of patients getting this particular infection after stem cell injections were performed outside the U.S.," Charles Daley, MD, an author of the report and head of the division of mycobacterial and respiratory infections at National Jewish Health, said in a hospital press release.

All three patients were still undergoing treatment as of March. No additional cases have been identified.

Daly and his colleagues subsequently conducted whole-gene sequencing (WGS) and phylogenetic analysis of isolates from patients A and B and found that both were clonal M abscessus subspecies massiliense, nearly identical (with only one single nucleotide polymorphism between the core genomes), and distinct from dominant circulating clones, even though the clinics were 167 miles apart. That's when they notified state public health officials and the Centers for Disease Control and Prevention (CDC).

The authors of the report suspect the infections in patient A and B could have been caused by a common contaminated source (such as the product, reagents, or equipment used in the procedures). Attempts by the Colorado Department of Public Health and Environment to identify the product and gather more information about its administration have been unsuccessful, they said. The next steps will be to perform WGS on isolates from patient C and conduct prospective case finding.

"Providers and public health agencies need to be aware of the risk forM. abscessusinfections from stem cell treatments for indications not approved by the Food and Drug Administration and maintain vigilance for similar cases," the authors wrote. "They also are advised to provide guidance for persons considering medical tourism."

Infections are among the many complications experienced by US residents who travel abroad for medical care. In a 2016 investigation reported in MMWR, CDC investigators described a multistate outbreak of M abscessus infections in 21 people who had undergone cosmetic surgery in the Dominican Republic. The CDC urges anyone who is considering medical tourism to consult their doctor first.

Providers and public health agencies need to be aware of the risk forM. abscessusinfections from stem cell treatments for indications not approved by the Food and Drug Administration and maintain vigilance for similar cases.

Excerpt from:
Three drug-resistant infections in US tied to stem-cell injections in Mexico - University of Minnesota Twin Cities

Recommendation and review posted by G. Smith

Stem Cell Differentiation: Creative Biolabs Reorganizes Its Neural Differentiation Services – openPR

Posted: May 15, 2024 at 2:33 am

Last month, Creative Biolabs streamlined old resources and infused them with innovations to launch a comprehensive suite of neural differentiation services. New York, USA - May 14, 2024 - As a global leader in biotechnology services, Creative Biolabs has introduced a fresh array of stem cell neural differentiation services, aligning with the latest advancements in neuroscience and catering to the evolving needs of its clients.

Image: https://www.getnews.info/uploads/0c59d26f78bf6dd58aafee5bc68d7d8c.jpg

"To understand the status and direction of neuronal differentiation, we introduced neuronal marker [https://neurost.creative-biolabs.com/neuronal-marker-antibody.htm] technologies to monitor the expression of specific neuronal markers during neural differentiation," explained an expert from Creative Biolabs' Neuroscience Research Department.

At Creative Biolabs, various neuronal markers are analyzed to study diverse neuronal functions for investigating neurological disease pathogenesis, such as cholinergic neuron markers CHT1 and CHA, axonal markers KIF5B and DYNC1H1, etc.

Neurological disease ex vivo models are mainly developed from primary neuronal cultures or induced pluripotent stem cells (iPSCs) sourced from patients. "iPSCs are the rising stars in neuroscience research," the expert added. "And the differentiation methods have also been enhanced by the technological recombination of Creative Biolabs."

Creative Biolabs achieved mastery in neuronal cell differentiation from iPSCs [https://www.creative-biolabs.com/stem-cell-therapy/neuronal-cells-differentiation-from-ipsc.htm], offering the capability to generate a diverse array of neuronal cell types from iPSCs, encompassing cortical, dopaminergic, motor, and sensory neurons. "The principle lies in the interaction of activation and inhibition of various developmental signaling pathways, which is crucial for regulating hiPSC neural differentiation."

At Creative Biolabs, strategies for differentiation of iPSC [https://www.creative-biolabs.com/stem-cell-therapy/ipsc-differentiation-services.htm] extend to generating diverse cell types such as hepatocytes, cardiomyocytes, and digestive system cells. "We've optimized the differentiation protocols and workflows to cater to the needs of both large-scale and small-scale projects, ensuring the quality of the differentiated cells remains uncompromised."

Furthermore, Creative Biolabs is dedicated to providing more advanced, reliable, and customized ex vivo modeling solutions. With Creative Biolabs' differentiation technologies, clients gain access to a myriad of fully functional neuronal models, encompassing disease models, drug screening models, and neurotoxicity assessment models.

These models serve as valuable tools for investigating a range of neurological disorders, including Parkinson's disease, Alzheimer's disease, stroke, and more, thereby offering a one-stop platform for exploring disease mechanisms. "In addition to delivering high-quality models, Creative Biolabs extends its services with comprehensive technical support, such as customized experimental design and data analysis."

For more iPSC differentiation services, please visit https://www.creative-biolabs.com/stem-cell-therapy.

About Creative Biolabs

Creative Biolabs embarks on its conference journey this year with the PPA Science & Technology Fair. Join us to share expertise and explore innovative biotechnologies and tools with experts from various fields. Media Contact Company Name: Creative Biolabs Contact Person: Candy Swift Email: Send Email [http://www.universalpressrelease.com/?pr=stem-cell-differentiation-creative-biolabs-reorganizes-its-neural-differentiation-services] Phone: 1-631-830-6441 Country: United States Website: https://www.creative-biolabs.com/stem-cell-therapy

This release was published on openPR.

Read the rest here:
Stem Cell Differentiation: Creative Biolabs Reorganizes Its Neural Differentiation Services - openPR

Recommendation and review posted by G. Smith


Page 9«..891011..2030..»